The announcement notes that St Vincent's is prohibited from releasing price-sensitive data such as response rates via a video presentation, but it is not difficult to read between the lines.
Responses must be very good, otherwise Noxopharm would not initiate a randomised Phase 2 trial!
We will know the exact state of affairs when St Vincent's presents at a major conference in June. If Veyonda improves the performance of LuPSMA, which appears to be the case, then Novartis will be very interested indeed!
This is great news for prostate cancer patients; and for Noxopharm shareholders.
Ann: Principal Investigator Discusses LuPIN-1 Study, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $555 | 5.296K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 95000 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 151971 | 2 |
View Market Depth
| Last trade - 15.18pm 22/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
